Re-Irradiation in Patients with Recurrent Rectal Cancer is Safe and Feasible.
Re-Irradiation in Patients with Recurrent Rectal Cancer is Safe and Feasible.
复制标题
复发性直肠癌患者再次放疗是安全可行的。
DOI：
10.1245/s10434-021-10070-6
复制
发表时间：
2021-09
影响因子：
3.7
通讯作者：
van Etten B
中科院分区：
文献类型：
--
作者：
Dijkstra EA;Mul VEM;Hemmer PHJ;Havenga K;Hospers GAP;Muijs CT;van Etten B
对于复发性直肠癌（RRC）患者的最佳治疗方案尚未达成共识。本研究的目的是评估我们中心的RRC患者再次照射后的毒性和肿瘤学结局。还研究了临床（cCR）和病理学完全缓解（pCR）率和根治性。在2010年1月至2018年12月期间，对61例局部晚期RRC患者进行了治疗和回顾性分析。低危原发性直肠癌患者接受30.0-30.6戈伊（reCRT）或50.0-50.4戈伊化放疗（CRT）。两组患者均同时接受卡培他滨治疗。总共有60名患者接受了处方的新辅助（化疗）放疗，随后进行了手术，其中reRCT组有35名患者（58.3%），长疗程CRT组有25名患者（41.7%）。两组之间的总生存期（p = 0.82）、无病生存期（p = 0.63）和局部无复发生存期（p = 0.17）无显著差异。长期CRT组患者放疗后报告的皮肤毒性更多（p = 0.040）。在晚期毒性方面未观察到差异。在长疗程CRT组中，观察到cCR率显著更高（p = 0.029）;然而，pCR率无差异（p = 0.66）。在毒性和肿瘤学结局方面，RRC患者的再照射治疗与长期CRT治疗相当。在reCRT组中，观察到cCR较少，但pCR无差异。本研究的结果提示，对RRC患者进行再照射是安全可行的。在线版本包含补充材料，可通过10.1245/s10434-021-10070-6获得。
There is no consensus yet for the best treatment regimen in patients with recurrent rectal cancer (RRC). This study aims to evaluate toxicity and oncological outcomes after re-irradiation in patients with RRC in our center. Clinical (cCR) and pathological complete response (pCR) rates and radicality were also studied. Between January 2010 and December 2018, 61 locally advanced RRC patients were treated and analyzed retrospectively. Patients received radiotherapy at a dose of 30.0–30.6 Gy (reCRT) or 50.0–50.4 Gy chemoradiotherapy (CRT) in cases of no prior irradiation because of low-risk primary rectal cancer. In both groups, patients received capecitabine concomitantly. In total, 60 patients received the prescribed neoadjuvant (chemo)radiotherapy followed by surgery, 35 patients (58.3%) in the reRCT group and 25 patients (41.7%) in the long-course CRT group. There were no significant differences in overall survival (p = 0.82), disease-free survival (p = 0.63), and local recurrence-free survival (p = 0.17) between the groups. Patients in the long-course CRT group reported more skin toxicity after radiotherapy (p = 0.040). No differences were observed in late toxicity. In the long-course CRT group, a significantly higher cCR rate was observed (p = 0.029); however, there was no difference in the pCR rate (p = 0.66). The treatment of RRC patients with re-irradiation is comparable to treatment with long-course CRT regarding toxicity and oncological outcomes. In the reCRT group, less cCR was observed, although there was no difference in pCR. The findings in this study suggest that it is safe and feasible to re-irradiate RRC patients. The online version contains supplementary material available at 10.1245/s10434-021-10070-6.
登录
查看更多内容
DOI：
10.1016/s0360-3016(97)00340-4
发表时间：
1997-10-01
影响因子：
7
作者：
Mohiuddin, M;Marks, GM;Marks, J
通讯作者：
Marks, J
影响因子：
158.5
作者：
Sauer, R;Becker, H;Raab, R
通讯作者：
Raab, R
影响因子：
45.3
作者：
Braendengen, Morten;Tveit, Kjell M.;Glimelius, Bengt
通讯作者：
Glimelius, Bengt
影响因子：
3.8
作者：
Bosman, S. J.;Vermeer, T. A.;Rutten, H. J. T.
通讯作者：
Rutten, H. J. T.
影响因子：
3.9
作者：
Endreseth, BH;Myrvold, HE;Wibe, A
通讯作者：
Wibe, A